We conducted a genome-wide association (GWA) study of lung cancer comparing 511,919 SNP genotypes in 1,952 cases and 1,438 controls. The most significant association was attained at 15q25.1 (rs8042374; P ¼ 7.75 Â 10 À12 ), confirming recent observations. Pooling data with two other GWA studies (5,095 cases, 5,200 controls) and with replication in an additional 2,484 cases and 3,036 controls, we identified two newly associated risk loci mapping to 6p21.33 (rs3117582, BAT3-MSH5; P combined ¼ 4.97 Â 10 À10 ) and 5p15.33 (rs401681, CLPTM1L; P combined ¼ 7.90 Â 10 À9 ).
with previous studies, 15q25.1 SNPs were most strongly associated; excluding these SNPs, 98 were associated at P r 10 À4 .
To replicate associations, we are now genotyping the most strongly associated SNPs in an additional case-control series. In the interim, we have sought to identify new associations by conducting a metaanalysis pooling our UK-GWA study with data from two other studies: the IARC-GWA study of 1,989 cases and 2,625 controls 2 , summary data from which is publicly available; and the Texas-GWA study of 1,154 non-small-cell lung cancer cases and 1,137 controls 1 . In both studies genotyping was done using Illumina HumanHap300 BeadChips. Pooling was based on the 223,891 autosomal SNPs genotyped in all three GWA studies that had MAFs 4 1% and no departure from HWE (P o 10 À5 in cases or controls).
We derived meta-analysis odds ratios (ORs) and confidence intervals (CIs), and associated P values (Supplementary Methods). As expected, the strongest associations were obtained for SNPs mapping to 15q25. Fig. 1 ). For the combined dataset l was 1.04 and 0.92 under fixed and random effects models, respectively (Supplementary Fig. 1 ), providing little evidence of confounding from population substructure as a source of bias in our meta-analysis.
Aside from 15q25, the strongest evidence for a lung cancer risk loci was found at 6p21.33 ( Supplementary Fig. 2 We observed strong support for an association between rs3117582 and rs3131379 and risk in the UK-GWA and IARC-GWA studies, with P values in each of borderline genome-wide significance (P ¼ 6.24 Â 10 À6 and 4.41 Â 10 À6 , respectively). Support was limited in the Texas-GWA study, reflected in the random-effects model (P ¼ 6.63 Â 10 À3 , P het ¼ 0.02 and P ¼ 0.013, P het ¼ 0.03 for rs3117582 and rs3131379, respectively). As all three GWA studies were based on subjects with European ancestry, ancestry-related differences are unlikely to underlie between-study heterogeneity, and the nonsignificant association in the Texas-GWA study may reflect study power, especially as these SNPs have low MAFs. To further validate the association between 6p and risk, we genotyped rs3117582 in an additional 2,484 cases and 3,036 controls (UK-Replication series; Supplementary Methods). Genotypes were obtained for 2,448 (98.6%) cases and 2,983 (98.3%) controls. As previously, the C allele was associated with a significantly increased risk (OR ¼ 1.16, 95% CI ¼ 1.04-1.29; P ¼ 7.30 Â 10 À3 ). Pooling data from all series provided unequivocal evidence for a relationship between rs3117582 and lung cancer risk (P ¼ 4.97 Â 10 À10 , P het ¼ 0.02, I 2 ¼ 71%; Fig. 1 ). ORs associated with AC and CC genotypes were 1.20 (95% CI ¼ 1.11-1.29, P ¼ 7.12 Â 10 -6 ; P het ¼ 0.06, I 2 ¼ 60%) and 1.80 
rs3117582 (31,728,499 bp) localizes to intron 1 of BAT3 and rs3131379 (31,829,012 bp) localizes to intron 10 of MSH5 at 6p21.33 (Fig. 2) . Genotypes are highly correlated (r 2 ¼ 0.99), hence on the basis of flanking recombination hot spots they define a single locus at 31,676,001-32,303,001 bp. The association could be mediated through LD with a number of transcripts; however, BAT3 and MSH5 both represent strong candidates for lung cancer susceptibility. BAT3 is implicated in apoptosis and the protein complexes with E1A-binding protein p300, required for acetylation of p53 in response to DNA damage 5 . MSH5 is involved in DNA mismatch repair (MMR) and meiotic recombination, and deficiency of MMR has been documented to have a role in lung cancer [6] [7] [8] .
There is some evidence for a risk locus at 6p22. random effects P ¼ 3.43 Â 10 À7 ; Supplementary Table 1 and Fig. 2) . LD across 6p21.33-6p22.1 is extensive, and although recombination rates across the region are compatible with an independent susceptibility locus, the moderate LD between rs9295740 and both rs3117582 and rs3131379 (r 2 values of 0.38 and 0.39, respectively) suggests that the associations may be mediated through correlation with the same causal variant. The most consistent evidence for a new disease locus outside 6p was attained at 5p15.33 (rs401681; OR ¼ 0.88, 95% CI ¼ 0.83-0.93; P ¼ 4.40 Â 10 À6 ; P het ¼ 0.94, I 2 ¼ 0%; Supplementary Table 1) . rs401681 localizes to intron 13 of CLPTM1L 9 within a 60-kb region of LD (1,353,580-1,412,838 bp; Fig. 2 and Supplementary Fig. 3 online) frequently amplified in early-stage NSCLC 10 . Genotyping rs401681 in the UK-Replication series provided further validation of the association. We obtained genotypes for 2,396 (99.7%) cases and 3,001 (98.8%) controls. The A allele was associated with a significantly decreased risk (OR ¼ 0.92, 95% CI ¼ 0.88-0.97; P ¼ 4.95 Â 10 À4 ). Pooling data from all series provided unequivocal evidence for a relationship between rs401681 and risk (OR ¼ 0.87, 95% CI ¼ 0.84-0.92; P ¼ 7.90 Â 10 À9 ; P het ¼ 0.99, I 2 ¼ 0%; Fig. 1 ). ORs associated with GA and AA genotypes were 0.86 (95% CI ¼ 0.80-0.92; P ¼ 2.12 Â 10 À5 , P het ¼ 0.53, I 2 ¼ 0%) and 0.77 (95% CI ¼ 0.70-0.84; P ¼ 3.54 Â 10 À8 , P het ¼ 0.99, I 2 ¼ 0%), respectively.
We examined for clinicopathological relationships with rs3117582 and rs401681 in the UK and Texas datasets. The only significant association was between rs3117582 and family history of lung cancer (P ¼ 0.03), nonsignificant after adjustment for multiple comparisons (Supplementary Table 2 online). These data suggest that, despite differences in the biology of NSCLC and SCLC, the causal variants affect the risk of all forms of lung cancer, compatible with epidemiological data showing that familial lung cancer risks are not subtype dependent and that intrafamilial histological concordance is poor 11 .
The power of our analysis to identify the 15q25.1 and 6p loci at P ¼ 2.0Â10 À7 was high (480%). In contrast, power to detect alleles with smaller effects and MAFs (for example, those of rs401681) was low. By implication, variants with similar profiles may constitute a larger class of susceptibility loci, whether because of smaller effects or submaximal LD with tagging SNPs.
The 15q25.1 and 6p variants are unlikely to account for 41% of the familial risk, hence a large number of low-risk variants remain to be identified. Further efforts to expand the scale of GWA meta-analyses, in terms of both sample size and SNP coverage, and to increase the number of SNPs taken forward to large-scale replication should identify additional risk variants.
Note: Supplementary information is available on the Nature Genetics website. 
